Nicotinamide and insulin secretion in normal subjects

P. J. Bingley, G. Caldas, R. Bonfanti, E. A M Gale

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Nicotinamide has been given both before and after clinical onset of Type 1 (insulin-dependent) diabetes mellitus in an attempt to prolong beta-cell survival. Nicotinic acid, structurally similar to nicotinamide, induces insulin resistance and increases insulin secretion in healthy individuals. It is not known if nicotinamide has similar effects. Since insulin secretion, as measured by the acute insulin response to intravenous glucose, is used to predict diabetes and to monitor therapy, the effects of nicotinamide must be established before trials in individuals at high risk of progression to Type 1 diabetes can be interpreted. Intravenous tolerance tests were performed according to the ICARUS standard protocol in 10 healthy, adult subjects (age 32±5.7 years) before and after 14 days of treatment with nicotinamide 25 mg · kg-1 · day-1. The acute insulin response after nicotinamide did not differ from the control study, whether measured as the incremental 0-10 min insulin area (278±142 vs 298±130mU · l-1 · 10 min-1) or as the 1±3 min insulin level (78±39 vs 81±44 mU/l). The late insulin response was equally unaffected, as were basal insulin (5.2±1.6 vs 5.6±2.1 mU/l) and glucose (5.0±0.4 vs 4.9±0.2 mmol/l) levels and glucose disposal rates (1.98±0.88 vs 2.04±0.68%/min). Nicotinamide does not affect insulin secretion and glucose kinetics in normal subjects, confirming its suitability for trials designed to delay or prevent the onset of Type 1 diabetes.

Original languageEnglish
Pages (from-to)675-677
Number of pages3
JournalDiabetologia
Volume36
Issue number7
DOIs
Publication statusPublished - Jul 1993

Fingerprint

Niacinamide
Insulin
Type 1 Diabetes Mellitus
Glucose
Niacin
Insulin Resistance
Cell Survival
Healthy Volunteers

Keywords

  • insulin secretion
  • intravenous glucose tolerance test
  • niacinamide
  • Nicotinamide
  • prevention

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Nicotinamide and insulin secretion in normal subjects. / Bingley, P. J.; Caldas, G.; Bonfanti, R.; Gale, E. A M.

In: Diabetologia, Vol. 36, No. 7, 07.1993, p. 675-677.

Research output: Contribution to journalArticle

Bingley, PJ, Caldas, G, Bonfanti, R & Gale, EAM 1993, 'Nicotinamide and insulin secretion in normal subjects', Diabetologia, vol. 36, no. 7, pp. 675-677. https://doi.org/10.1007/BF00404080
Bingley, P. J. ; Caldas, G. ; Bonfanti, R. ; Gale, E. A M. / Nicotinamide and insulin secretion in normal subjects. In: Diabetologia. 1993 ; Vol. 36, No. 7. pp. 675-677.
@article{2766373a4c67411499096d1615fc9690,
title = "Nicotinamide and insulin secretion in normal subjects",
abstract = "Nicotinamide has been given both before and after clinical onset of Type 1 (insulin-dependent) diabetes mellitus in an attempt to prolong beta-cell survival. Nicotinic acid, structurally similar to nicotinamide, induces insulin resistance and increases insulin secretion in healthy individuals. It is not known if nicotinamide has similar effects. Since insulin secretion, as measured by the acute insulin response to intravenous glucose, is used to predict diabetes and to monitor therapy, the effects of nicotinamide must be established before trials in individuals at high risk of progression to Type 1 diabetes can be interpreted. Intravenous tolerance tests were performed according to the ICARUS standard protocol in 10 healthy, adult subjects (age 32±5.7 years) before and after 14 days of treatment with nicotinamide 25 mg · kg-1 · day-1. The acute insulin response after nicotinamide did not differ from the control study, whether measured as the incremental 0-10 min insulin area (278±142 vs 298±130mU · l-1 · 10 min-1) or as the 1±3 min insulin level (78±39 vs 81±44 mU/l). The late insulin response was equally unaffected, as were basal insulin (5.2±1.6 vs 5.6±2.1 mU/l) and glucose (5.0±0.4 vs 4.9±0.2 mmol/l) levels and glucose disposal rates (1.98±0.88 vs 2.04±0.68{\%}/min). Nicotinamide does not affect insulin secretion and glucose kinetics in normal subjects, confirming its suitability for trials designed to delay or prevent the onset of Type 1 diabetes.",
keywords = "insulin secretion, intravenous glucose tolerance test, niacinamide, Nicotinamide, prevention",
author = "Bingley, {P. J.} and G. Caldas and R. Bonfanti and Gale, {E. A M}",
year = "1993",
month = "7",
doi = "10.1007/BF00404080",
language = "English",
volume = "36",
pages = "675--677",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "7",

}

TY - JOUR

T1 - Nicotinamide and insulin secretion in normal subjects

AU - Bingley, P. J.

AU - Caldas, G.

AU - Bonfanti, R.

AU - Gale, E. A M

PY - 1993/7

Y1 - 1993/7

N2 - Nicotinamide has been given both before and after clinical onset of Type 1 (insulin-dependent) diabetes mellitus in an attempt to prolong beta-cell survival. Nicotinic acid, structurally similar to nicotinamide, induces insulin resistance and increases insulin secretion in healthy individuals. It is not known if nicotinamide has similar effects. Since insulin secretion, as measured by the acute insulin response to intravenous glucose, is used to predict diabetes and to monitor therapy, the effects of nicotinamide must be established before trials in individuals at high risk of progression to Type 1 diabetes can be interpreted. Intravenous tolerance tests were performed according to the ICARUS standard protocol in 10 healthy, adult subjects (age 32±5.7 years) before and after 14 days of treatment with nicotinamide 25 mg · kg-1 · day-1. The acute insulin response after nicotinamide did not differ from the control study, whether measured as the incremental 0-10 min insulin area (278±142 vs 298±130mU · l-1 · 10 min-1) or as the 1±3 min insulin level (78±39 vs 81±44 mU/l). The late insulin response was equally unaffected, as were basal insulin (5.2±1.6 vs 5.6±2.1 mU/l) and glucose (5.0±0.4 vs 4.9±0.2 mmol/l) levels and glucose disposal rates (1.98±0.88 vs 2.04±0.68%/min). Nicotinamide does not affect insulin secretion and glucose kinetics in normal subjects, confirming its suitability for trials designed to delay or prevent the onset of Type 1 diabetes.

AB - Nicotinamide has been given both before and after clinical onset of Type 1 (insulin-dependent) diabetes mellitus in an attempt to prolong beta-cell survival. Nicotinic acid, structurally similar to nicotinamide, induces insulin resistance and increases insulin secretion in healthy individuals. It is not known if nicotinamide has similar effects. Since insulin secretion, as measured by the acute insulin response to intravenous glucose, is used to predict diabetes and to monitor therapy, the effects of nicotinamide must be established before trials in individuals at high risk of progression to Type 1 diabetes can be interpreted. Intravenous tolerance tests were performed according to the ICARUS standard protocol in 10 healthy, adult subjects (age 32±5.7 years) before and after 14 days of treatment with nicotinamide 25 mg · kg-1 · day-1. The acute insulin response after nicotinamide did not differ from the control study, whether measured as the incremental 0-10 min insulin area (278±142 vs 298±130mU · l-1 · 10 min-1) or as the 1±3 min insulin level (78±39 vs 81±44 mU/l). The late insulin response was equally unaffected, as were basal insulin (5.2±1.6 vs 5.6±2.1 mU/l) and glucose (5.0±0.4 vs 4.9±0.2 mmol/l) levels and glucose disposal rates (1.98±0.88 vs 2.04±0.68%/min). Nicotinamide does not affect insulin secretion and glucose kinetics in normal subjects, confirming its suitability for trials designed to delay or prevent the onset of Type 1 diabetes.

KW - insulin secretion

KW - intravenous glucose tolerance test

KW - niacinamide

KW - Nicotinamide

KW - prevention

UR - http://www.scopus.com/inward/record.url?scp=0027255816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027255816&partnerID=8YFLogxK

U2 - 10.1007/BF00404080

DO - 10.1007/BF00404080

M3 - Article

C2 - 8359586

AN - SCOPUS:0027255816

VL - 36

SP - 675

EP - 677

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 7

ER -